斯奇康与顺铂对照治疗肺癌合并胸水的临床观察

Clinical Study on Siqkang Compare with Cislatin Therapy for Patients with Lung Cancer Complicationg Hydrothorax

目的 评价斯奇康与顺铂对照治疗肿瘤合并胸水的疗效和毒性。方法 将 38例肺癌合并胸水的患者随机分为治疗和对照组。治疗组 19例 ,胸腔内注射斯奇康 10 mg、地塞米松 10 mg;对照组 19例 ,胸腔内注射顺铂 80 mg、地塞米松 10 mg。结果 治疗组完全缓解 (CR) 4 2 .1% ,部分缓解 (PR) 4 2 .1% ,有效率 (CR+PR) 84 .2 % ;对照组完全缓解10 .5 % ,部分缓解 6 3.2 % ,有效率 73.7%。两组完全缓解差异具有统计学意义 (χ2 =4 .886 ,P<0 .0 5 )。结论 斯奇康治疗肺癌合并胸水疗效肯定 ,不良反应轻。

Objective To evaluate the efficacy and toxicity of lung cancer treatment in the malignant pleural effusion.Methods 38 patients were divided into 2 groups. Tretment group:Siqkang 10 mg and dexamethason 10 mg; control group:cislatin 80 mg and dexamethason 10 mg. Results The overall response rate was 84.2% (16/19) in treatment group, including with complete response rate 42.1%(8/19) and partial response rate 42.1%(8/19). 73.7%(14/19) in control group, including 10.5%(2/19) with complete response rate and 63.2%(12/19) with partial response rate. Treatment group had a higher complete responge rate compared to contral group (χ 2=4.886, P<0.05). The side effects are mild. Conclusion This study shows that siquang is effective for control of the lung cancer malignant pleural effusions.